Drug Profile
Etanercept biosimilar - Amega Biotech
Alternative Names: Enerceptan; Recombinant etanercept - Amega BiotechLatest Information Update: 17 Nov 2021
Price :
$50
*
At a glance
- Originator Amega Biotech
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Rheumatoid arthritis
Most Recent Events
- 25 Sep 2020 Etanercept biosimilar is in active development for rheumatoid arthritis in Argentina (Amega Biotech website, September 2020)
- 01 Sep 2017 Amega Biotech completes the phase III GEMENE trial in Rheumatoid arthritis (Combination therapy) in Argentina (NCT03332719)
- 19 Aug 2013 Investigation in Rheumatoid arthritis in Argentina (Parenteral)